Close this search box.

Science spotlight: Tumor T cell restriction mechanism, plus programmable RNA excision

ARTICLE | Discovery & Translation

BioCentury’s roundup of translational innovations

By Danielle Golovin, Senior Biopharma Analyst

April 27, 2024 12:03 AM UTC

Serial entrepreneur Lieping Chen led a study in Science Immunology that identified a phospholipase that reduces response to immunotherapy by blocking T cell infiltration into tumors.

Authors from NextCure Inc. (NASDAQ:NXTC), Normunity Inc. and Yale University performed a genome-wide screen of over 1,000 soluble human proteins enriched in the tumor microenvironment and identified PLA2G10 as a T cell excluder that is highly expressed in several cancers…